The development of composite circulating biomarker models for use in anticancer drug clinical development

International Journal of Cancer

Volumn 128, Issue 8, 2011, Pages 1843-1851

  Lancashire, Lee J ^a   Roberts, Darren L ^a   Dive, Caroline ^a,b   Renehan, Andrew G ^a,b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

artificial neural network; biomarkers; insulin like growth factors; receiver operator characteristics; support vector machine

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACCURACY; ACROMEGALY; ADULT; AGED; ARTICLE; ARTIFICIAL NEURAL NETWORK; CALIBRATION; CLINICAL DECISION MAKING; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE;

ADULT; AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MODELS, STATISTICAL; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79951966467     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25513     Document Type: Article

References (47)

1. Sawyers CL,. The cancer biomarker problem. Nature 2008; 452: 548-52. (Pubitemid 351483368)
2. Kattan MW,. Evaluating a new marker's predictive contribution. Clin Cancer Res 2004; 10: 822-4. (Pubitemid 38198879)
3. Yeatman TJ, Mule J, Dalton WS, Sullivan D,. On the eve of personalized medicine in oncology. Cancer Res 2008; 68: 7250-2.
4. Backen AC, Cummings J, Mitchell C, Jayson G, Ward TH, Dive C,. 'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. J Immunol Methods 2009; 342: 106-14.
5. Royston P, Sauerbrei W,. Building multivariable regression models with continuous covariates in clinical epidemiologyâwith an emphasis on fractional polynomials. Methods Inf Med 2005; 44: 561-71. (Pubitemid 41345381)
6. Lisboa PJ, Taktak AF,. The use of artificial neural networks in decision support in cancer: a systematic review. Neural Netw 2006; 19: 408-15. (Pubitemid 44183627)
7. Lancashire LJ, Lemetre C, Ball GR,. An introduction to artificial neural networks in bioinformaticsâapplication to complex microarray and mass spectrometry datasets in cancer studies. Brief Bioinform 2009; 10: 315-29.
8. Noble WS,. What is a support vector machine? Nat Biotechnol 2006; 24: 1565-7. (Pubitemid 44967481)
9. Jones JI, Clemmons DR,. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
10. Renehan AG, Toogood AA, Ryder WD, Jones J, Potten CS, O'Dwyer ST, Shalet SM,. Paradoxical elevations in serum IGF-II and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides. Clin Endocrinol (Oxf) 2001; 55: 469-75. (Pubitemid 32955484)
11. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE,. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994; 41: 85-93. (Pubitemid 24232532)
12. Renehan AG, Frystyk J, Flyvbjerg A,. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006; 17: 328-36. (Pubitemid 44397568)
13. Gram IT, Norat T, Rinaldi S, Dossus L, Lukanova A, Tehard B, Clavel-Chapelon F, van Gils CH, van Noord PA, Peeters PH, Bueno-de-Mesquita HB, Nagel G, et al. Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. Int J Obes (Lond) 2006; 30: 1623-31. (Pubitemid 44657836)
14. Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST,. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000; 83: 1344-50.
15. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG,. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993; 76: 1031-5. (Pubitemid 23110857)
16. Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J, Karasik A,. Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer 1996; 73: 1069-73. (Pubitemid 26131226)
17. Reeve JG, Payne JA, Bleehen NM,. Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours. Br J Cancer 1990; 61: 727-31. (Pubitemid 20151340)
18. Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M,. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res 2008; 14: 8263-9.
19. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y,. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93: 1054-61. (Pubitemid 32717537)
20. Toogood AA, Jones J, O'Neill PA, Thorner MO, Shalet SM,. The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic- pituitary disease. Clin Endocrinol (Oxf) 1998; 48: 569-76. (Pubitemid 28252993)
21. Renehan AG, Atkin WS, O'Dwyer S T, Shalet SM,. The effect of cigarette smoking use and cessation on serum insulin-like growth factors. Br J Cancer 2004; 91: 1525-31. (Pubitemid 39486358)
22. Renehan AG, Frystyk J, Howell A, O'Dwyer S T, Shalet SM, Flyvbjerg A,. The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. Growth Horm IGF Res 2007; 17: 210-9. (Pubitemid 46888319)
23. Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A,. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3. J Clin Endocrinol Metab 2001; 86: 1091-8. (Pubitemid 32322987)
24. Morrell DJ, Dadi H, More J, Taylor AM, Dabestani A, Buchanan CR, Holder AT, Preece MA,. A monoclonal antibody to human insulin-like growth factor-I: characterization, use in radioimmunoassay and effect on the biological activities of the growth factor. J Mol Endocrinol 1989; 2: 201-6. (Pubitemid 19117456)
25. Renehan AG, Jones J, O'Dwyer ST, Shalet SM,. Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method. Growth Horm IGF Res 2003; 13: 341-6. (Pubitemid 37493325)
26. Hosmer DW, Lemeshow S,. Applied Logistic Regression. New York: Wiley, 2000.
27. Royston P, Ambler G, Sauerbrei W,. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28: 964-74. (Pubitemid 29525041)
28. Werbos P,. Beyond regression: new tools for prediction and analysis in the behavioral science. Cambridge: Harvard University, 1974.
29. Rumelhart DE, Hinton GE, Williams RJ,. Learning representations by back-propagating errors. Nature 1986; 323: 533-36. (Pubitemid 16025374)
30. Lancashire L, Schmid O, Shah H, Ball G,. Classification of bacterial species from proteomic data using combinatorial approaches incorporating artificial neural networks, cluster analysis and principal components analysis. Bioinformatics 2005; 21: 2191-9. (Pubitemid 40731570)
31. Lancashire LJ, Rees RC, Ball GR,. Identification of gene transcript signatures predictive for estrogen receptor and lymph node status using a stepwise forward selection artificial neural network modelling approach. Artif Intell Med 2008; 43: 99-111.
32. Shao J,. Linear model selection by cross-validation. J Am Stat Assoc 1993; 88: 486-94.
33. Xu QS, Liang YZ, Du YP,. Monte Carlo cross-validation for selecting a model and estimating the prediction error in multivariate calibration. J Chemom 2004; 18: 112-20.
34. Efron B,. How biased is the apparent eroor rate of a prediction rule? J Am Stat Assoc 1986; 81: 461-70.
35. Hanley JA, McNeil BJ,. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43. (Pubitemid 13033817)
36. Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS,. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-72; discussion 207-12. (Pubitemid 351193639)
37. Mallett S, Deeks JJ, Halligan S, Hopewell S, Cornelius V, Altman DG,. Systematic reviews of diagnostic tests in cancer: review of methods and reporting. BMJ 2006; 333: 413.
38. Ahmed FE,. Artificial neural networks for diagnosis and survival prediction in colon cancer. Mol Cancer 2005; 4: 29.
39. Dolgobrodov SG, Moore P, Marshall R, Bittern R, Steele RJ, Cuschieri A,. Artificial neural network: predicted vs observed survival in patients with colonic cancer. Dis Colon Rectum 2007; 50: 184-91. (Pubitemid 46227214)
40. Snow PB, Kerr DJ, Brandt JM, Rodvold DM,. Neural network and regression predictions of 5-year survival after colon carcinoma treatment. Cancer 2001; 91 (8 Suppl): 1673-8. (Pubitemid 32327947)
41. Bottaci L, Drew PJ, Hartley JE, Hadfield MB, Farouk R, Lee PW, Macintyre IM, Duthie GS, Monson JR,. Artificial neural networks applied to outcome prediction for colorectal cancer patients in separate institutions. Lancet 1997; 350: 469-72. (Pubitemid 27343301)
42. Grumett S, Snow P, Kerr D,. Neural networks in the prediction of survival in patients with colorectal cancer. Clin Colorectal Cancer 2003; 2: 239-44. (Pubitemid 36367311)
43. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A,. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006; 94: 1898-905. (Pubitemid 43882582)
44. Tan AH, Pan H,. Predictive neural networks for gene expression data analysis. Neural Netw 2005; 18: 297-306. (Pubitemid 40719531)
45. Schwarzer G, Vach W, Schumacher M,. On the misuses of artificial neural networks for prognostic and diagnostic classification in oncology. Stat Med 2000; 19: 541-61. (Pubitemid 30126883)
46. Byvatov E, Schneider G,. Support vector machine applications in bioinformatics. Appl Bioinformatics 2003; 2: 67-77.
47. Collinson F, Jayson G,. New therapeutic agents in ovarian cancer. Curr Opin Obstet Gynecol 2009; 21: 44-53.